Hypoglycemia risk reduction in type 1 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue SUPPL. 2, 2001, Pages

  Cryer, P E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Defective glucose counterregulation; Hypoglycemia unawareness; Hypoglycemia associated autonomic failure

Indexed keywords

ARTICLE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; PRIORITY JOURNAL; RISK FACTOR;

DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIA; RISK FACTORS;

EID: 0034968632     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18599     Document Type: Article

References (60)

1. Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release
2. Severe insulin-induced hypoglycemia associated with deficiencies in the release of counterregulatory hormones
3. How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes
4. Abnormal glucose counterregulation in insulin dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion
5. A reliable and reproducible test for adequate glucose counterregulation in type 1 diabetes
6. Contribution of autonomic neuropathy to reduced plasma adrenaline responses to hypoglycemia in IDDM: Evidence for a nonselective defect
7. Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from, prolonged hypoglycemia in humans
8. Brain glucose uptake and unawareness of hypoglycemia in patients with insulin dependent diabetes mellitus
9. Adaptation in brain glucose uptake following recurrent hypoglycemia
10. Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics
11. Restoration of hypoglycemia unawareness in patients with long duration insulin-dependent diabetes mellitus
12. Iatrogenic hypoglycemia as a cause of hypoglycemia-associated autonomic failure in IDDM: A vicious cycle
13. Hypoglycemia
14. Hypoglycemia is the limiting factor in the management of diabetes
15. Hypoglycemia-associated autonomic failure in insulin dependent diabetes mellitus
16. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM
17. Further defects in counterregulatory responses induced by recurrent hypoglycemia in IDDM
18. Counterregulatory adaptation to recurrent hypoglycemia in normal humans
19. Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans
20. Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses
21. Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans
22. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: A meta-analysis
23. Relative roles of insulin and hypoglycemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycemia in male and female humans
24. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia following institution of rational intensive therapy in IDDM
25. Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes mellitus
26. Correlation between minimal secretory capacity of pancreatic β-cells and stability of diabetic control
27. Lack of glucagon response to hypoglycemia in diabetes: Evidence for an intrinsic pancreatic alpha cell defect
28. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia
29. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after one episode of hypoglycemia in nondiabetic humans
30. Effect of the fast acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy
31. Frequency and symptoms of hypoglycemia experienced by patients with type 2 diabetes treated with insulin
32. Defective epinephrine and growth hormone responses in type 1 diabetes are stimulus specific
33. Impact of recent antecedent hypoglycemia on hypoglycemic cognitive dysfunction in nondiabetic humans
34. Decreased epinephrine responses to hypoglycemia during sleep
35. Use of uncooked cornstarch to avert nocturnal hypoglycemia in children and adolescents with type 1 diabetes
36. The British Diabetic Association Cohort Study. II. Cause-specific mortality in patients with insulin-treated diabetes mellitus
37. Compromised hormonal counterregulation, symptom awareness, and neurophysiological function after recurrent short-term episodes of insulin-induced hypoglycemia in IDDM patients
38. Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients
39. Reversibility of hypoglycemia unawareness in patients with an insulinoma
40. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms and cerebral dysfunction
41. Risk factors for severe hypoglycaemia in adult patients with type 1 diabetes - A prospective population based study
42. Brief twice weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus
43. Hypoglycemia per se stimulates sympathetic neural as well as adrenomedullary activity but, unlike the adrenomedullary response, the forearm sympathetic neural responses is not reduced following recent hypoglycemia
44. The dawn phenomenon in type 1 (insulin dependent) diabetes mellitus: Magnitude, frequency, variability, and dependence on glucose counterregulation and insulin sensitivity
45. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial
46. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
47. Hypoglycemia in the Diabetes Control and Complications Trial
48. A 6-year, randomized, controlled trial comparing sulfonylurea, insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy
49. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes
50. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus: The Stockholm Diabetes Intervention Study after 5 years
51. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus
52. Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM
53. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycemia
54. Glycemic thresholds for activation of glucose counter-regulatory systems are higher than the threshold for symptoms
55. Mechanisms of awareness of hypoglycemia: Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms
56. UKPDS 25: Autoantibodies to islet cell cytoplasma and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
57. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia
58. Complex carbohydrates in the prevention of nocturnal hypoglycaemia in diabetic children
59. Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy
60. Intermittent hypoglycemia impairs glucose counterregulation